$FMC: A 90% Guidance Cut, $4.3 Billion of Debt, and a Covenant Holiday That Ends December 31

On Thursday, October 15, FMC Corporation (NYSE: FMC), the agricultural sciences company behind the Rynaxypyr insecticide franchise, told the market its third-quarter revenue would be $65 million to $125 million. Its prior guidance for the quarter, issued in late July, was $840 million to $900 million. That is a cut of roughly 90% at the midpoint, announced two weeks before earnings. Adjusted EBITDA guidance went from positive $120-140 million to negative $510-565 million.

The stock closed at $5.62, down 30.5% on the day, on 32.6 million shares, nearly ten times the recent daily pace. It touched $4.85 intraday, a new 52-week low, and sits 82% below its 52-week high of $30.95. At its 52-week high of $30.95, the same share count was worth nearly $3.9 billion; the equity market value is now roughly $700 million.

Numbers like these usually mean fraud, a lost lawsuit, or a product recall. This is none of those. It is something more unusual: a company deliberately detonating its own quarter to fix a channel problem it admits it can no longer manage incrementally. Whether that is the beginning of the turnaround or the beginning of something worse depends almost entirely on a debt covenant calendar that most of the coverage has skipped.

What FMC Actually Announced

The mechanics matter, because the 90% figure is not quite what it looks like. Per the company's 8-K, the revised guidance includes an estimated $625-675 million in charges from what FMC calls "commercial actions": lowering the price of its own products already sitting in distributor warehouses in Brazil, Argentina, the United States and Canada, and scrapping its US selling model of high gross prices offset by high rebates in favor of simpler net pricing.

Translation: distributors are holding FMC inventory they bought at prices the market no longer supports, and they have stopped ordering more until it moves. FMC is now eating the difference, issuing concessions against product already in the channel, which accounting-wise lands as a direct hit to revenue. Strip those charges out and the arithmetic implies underlying sales of roughly $690-800 million, which is still below the $840-900 million the company guided to in July. So this is a demand miss with a channel write-down stacked on top, not one or the other.

The root cause is the one FMC has been managing in slow motion for two years: Rynaxypyr, its blockbuster diamide insecticide active ingredient, has come off patent, and generic competition has been collapsing market prices faster than FMC could work its higher-priced inventory through the system. In the announcement, FMC described distributors "seeking to operate with the lowest inventory levels FMC has experienced" while "rapid market price declines, driven in part by increased generic competition" widened the gap between what the channel paid for FMC product and what it can sell it for. Second-quarter revenue was already down 17% year over year, with North America down 22%, per the company's Q2 report.

CEO Pierre Brondeau's framing is that the company "addressed this issue incrementally over several quarters" and has concluded that only a comprehensive reset will restart replenishment orders. The pitch: take one catastrophic quarter, clear the channel at market prices, and enter 2027 with distributors actually ordering again.

Briefings like this land in members' inboxes before the market prices them in. Join AlphaBriefing free.

Why the Stock Is Not Trading on the Quarter

Here is the thing: a one-time, largely non-recurring channel reset at a company with a real product portfolio is survivable, even sensible. Markets reprice it and move on. What makes FMC different is the balance sheet underneath it, and one sentence buried on page three of the announcement: "While the company expects to be in compliance with covenants at September 30, 2026, the company intends to engage in discussions with its bank group on potential further modifications to its covenants over the next year."

That sentence is the actual story. FMC has already amended its credit agreement twice this year. Its leverage covenant is currently in a holiday period that was negotiated last spring, and that holiday has an end date. The company is not going back to its banks for comfort; it is going back because the math of this quarter makes the existing schedule unworkable. The next ten weeks are about the debt stack, the covenant clock, what the banks can extract this time, and what has to be true on October 29 and 30 for the equity to hold. That is where the position math lives.

The rest of this briefing is for paid members: the full debt and cash picture from the latest 10-Q, the exact covenant schedule and why the December 31 test as written looks unpassable without another amendment, the asset-sale levers FMC can still pull, the two dates to put on the calendar, and scenario-by-scenario price zones.

AlphaBriefing Paid gets you every investment thesis, scenario framework, and catalyst brief we publish, the analysis private intel clients pay four figures for, at a fraction of that.

Unlock the full briefing →